| Code | 5523D | ||||||||||
| MA number | 29/0472/16-S | ||||||||||
| Product Form: | tbl 100x2,5 mg (obal HDPE bez bezpečnost.uzáv.) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Orion Corporation, Finland | ||||||||||
| Therapeutic Class: | 29 - ANTIRHEUMATICA, ANTIPHLOGISTICA, ANTIURATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 09.11.2016 |
| Pediatric posology: | Yes |
| Dokument: |
Metotrexat_prirucka pre zdravotnickych pracovnikov.pdf
|
| Dokument: |
Metotrexat_Karta pacienta.pdf
|
| SPC: |
SPC_Trexan Neo tablety_12.2024.pdf
|
| PIL: |
PIL_Trexan Neo tablety_12.2024.pdf
|
| Safety feature | Yes |
| Data update: | 13.04.2021 |
